This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
On the global stage, AI and Machine Learning (ML) drove drug discovery and process optimisation, especially as large-scale pharma companies adopted AI for precision medicine. Building sophisticated laboratories, recruiting scientific talent, and collaborating with global research institutions are essential steps in this process.
Since it is likely this appropriations package will be one of the last meaningful pieces of legislation before the November elections, other policy priorities may be added to that final legislation as it gets closer to passage. 5378 More Transparency, Lower Costs Act in December 2023. The House passed H.R.
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.
Further, introduction of the Scheme for Promotion of R&D and Innovation in Pharma Med Tech Sector (PRIP) in September 2023 showcases the focus on creating an ecosystem for innovation and research. Due to the multiplicity of regulatory processes and multiple regulators, undertaking operations become complex and time consuming.
NHC 2024 Policy Priorities December 13, 2023 By: Allen Pinn, Coordinator, Policy The National Health Council (NHC) prides itself in providing a voice for the over 160 million people living with a chronic disease or disability and their caregivers. In 2023, the NHC continued its leadership in the health care space.
What Does the January 2023 Update Mean for Mifepristone Dispensing? As of January 2023, the US Food and Drug Administration (FDA) announced an update to the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Record the NDC and lot number from each medication package dispensed in the patient’s record.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content